A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be stored at ambient temperature. Recovery is by adding aqueous solution to the composition.
|
0. 18. A composition which is storage-stable at 20° C., comprising:
(1) a carrier substance which is water-soluble or water-swellable and
(2) at least one material to be stored which is dissolved in said carrier substance;
wherein said composition has the property that it exists in a glassy state when at 20° C.;
wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;
wherein said biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said
with proviso that when said at least one material comprises an enzyme, said enzyme comprises an enzyme selected from restriction enzymes, dehydrogenase enzymes, oxidase enzymes, and reductase enzymes.
0. 17. A composition which is storage-stable at 20° C., comprising:
(1) a carrier substance which is water-soluble or water-swellable and is in a glassy state;
(2) at least one material to be stored which is dissolved in said carrier substance;
wherein said composition exists in a glassy state at 20° C.;
wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C.;
wherein said purified biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto;
wherein said composition contains no more than 4 percent by weight of water; and
wherein said biological active material is not rennin.
0. 19. A composition which is storage-stable at 20° C., comprising:
(1) a carrier substance which is water-soluble or water-swellable and
(2) at least one material to be stored which is dissolved in said carrier substance;
wherein said composition has the property that it exists in a glassy state when at 20° C;
wherein said at least one material comprises a purified biologically active material that is unstable in aqueous solution at 20° C;
wherein said biologically active material is selected from the group consisting of peptides, proteins, nucleosides, nucleotides, dimers or oligomers of nucleosides or nucleotides, enzymes, enzyme cofactors and derivatives of any of the foregoing, said derivatives having one or more additional moieties bound thereto; and
wherein said biologically active material is not freeze stable; and
with proviso that when said at least one material comprises an enzyme, said enzyme comprises an enzyme selected from dehydrogenase enzymes, restriction enzymes, oxidase enzymes, and reductase enzymes.
0. 1. A composition which is storage stable at 20° C. comprising:
i) a carrier substance which is water-soluble or water-swellable and is in a glassy amorpous state;
ii) at least one material to be stored, which is unstable in aqueous solution at room temperature of 20° C. dissolved in said amorphous carrier substance, said composition existing in a glassy state at 20° C.
0. 2. A composition according to
0. 3. A composition according to
0. 4. A composition according to
0. 5. A composition according to
0. 6. A composition according to
0. 7. A composition according to
0. 8. A composition according to
0. 9. A composition according to
0. 10. A composition according to
0. 11. A composition according to
0. 12. A method of rendering a material storage stable a 20° C., which material is unstable in aqueous solution at room temperature of 20° C., comprising dissolving the material in a carrier substance which is water-soluble or water-swellable, or to a solution thereof, so that the material is dissolved in said carrier substance, and forming the resulting mixture into a glassy amorphous state, said mixture existing in said glassy state at 20° C.
0. 13. A method according to
0. 14. A method according to
0. 15. A method according to
0. 16. In a method of storing a material, which material is unstable in aqueous solution at 20° C., the improvement comprising dissolving the material in a carrier substance which is water-soluble or water-swellable, or in a solution thereof, so that the material is dissolved in said carrier substance, forming the resulting mixture into a glassy amorphous state and storing the mixture in said glassy amorphous state without refrigeration for at least one week.
|
where I is the initial LDH activity (units/ml) in the solution used to prepare the glass.
The preparation was assayed periodically for LDH activity, as described in Example 1. No loss of activity could be detected after 1 month storage at 25° C.
The glass temperature of the preparation was determined by differential scanning calorimetry as 32° C.
To 1 g Ficoll 400 were added 100 μl of a solution of EcoR I restriction endonuclease in 50% aqueous glycerol and a glass was prepared as described in Example 1. The final preparation was stored for 10 days in the laboratory with temperatures fluctuating between 20 and 30° C.
A quantity of the preparation equivalent to 2 units of enzyme, based on the assumption that the enzyme was still fully active, was dissolved in the following buffer: 100 mM Tris-HCl pH 7.5. 10 mM MgCl2. 50 mM NaCl. 0.1 mg/ml bovine serum albumin. An assay for enzyme activity was carried out by the following procedure (which is taken from LKB Laboratory Manual: LKB 2013 Miniphor Submarine Electrophoresis Unit 1985, Chapter 6). The solution was incubated with 1 μg lamda-DNA for 1 hour at 37° C. Electrophoresis of the incubation mixture was then carried out on Q.5% agarose gel in Tris/borate buffer in standard manner. The DNA breakdown bands observed on the gel corresponded exactly with those of a control run with a fresh enzyme solution.
A solution containing 100 mg/ml NADH and 33 mg/ml pyruvate was prepared. 0.4 ml of this solution were incorporated into 4 g of a sucrose glass and the mixture processed, as described in Example 2. The mixed glass was stored in 20 mg quantities in spectrophotometer cuvettes which were closed with sealing film and kept in a laboratory where the temperature fluctuated between 20 and 35° C. The glass was stored for 14 days.
For purposes of assay, the contents of a cuvette were dissolved in 2.7ml of 0.01M phosphate buffer (pH 7.0) and 0.1 ml of a LDH solution containing 1 unit/ml was added. The absorbance at 340 nm was recorded at 30 second intervals for a total period of 3 minutes and the temperature of the solution was measured. The apparent LDH enzyme activity was determined from the period during which the absorbance change was linear with time. The activity was calculated as in Example 1. A control assay was carried out with fresh solutions of NADH and pyruvate. The apparent activity obtained using the dissolved glass closely matched the control value.
The active material was glutamate dehydrogenase. 532 mg of Ficoll 400 DL as used to Example 1 was added to 20 ml of a glutamate dehydrogenase solution, containing 13.3 mg/ml protein. The protein:Ficoll ratio was therefore 1.2. The sample was then divided into eighty 0.25 ml portions and dried at 37° C. under reduced pressure (about 80% of atmospheric) for 24 hours. The sample was then divided into two batches of 40 vials. One batch was heated under reduced pressure for a further two hours at 60° C. The batches were then further subdivided and stored under a range of conditions (see below). Vials were periodically rehydrated by adding 2.23 ml of 50 mM Tris/HCl buffer at pH 7.5, containing 0.3 mM EDTA to give a solution which, assuming no loss of activity, would have contained 100 units of enzyme per ml. This was serially diluted to 1 unit/ml in the same buffer. The actual activity of the recovered enzyme was determined. The assay procedure for recovered enzyme made use of the following solutions:
Solutions
To carry out the assay 2.6 ml of solution 4.0.2 ml of solution 3 and 0.1 ml of solution 2 were mixed in a 3 ml cuvette. 0.1 ml of the recovered enzymes solution was added. The absorbance at 340 nm was observed over 5 minutes and the activity of the enzyme calculated from the change (ΔA) in absorbance during the 5 minute period. Activity was calculated using the following formula:
The results obtained are set out in the following Table in which “initial activity” denotes the activity of enzyme which was recovered after only a minimal period of storage. The activities are quoted as percentages of the theoretical value of activity assuming this had been retained fully. A quantity of a commercially freeze-dried glutamate dehydrogenase (whose activity before freeze drying was stated by the supplier) was divided into several portions and stored at 25° C. for varying periods and assayed in the same way. Its activity is also quoted as percentages of the theoretical activity. The results for this material ar included in the Table.
Process
Storage
Temp-
Temp-
Initial
Duration of Storage (weeks)
erature
erature
Activity
1
2
3
4
6
12
37° C.
ambient
97%
95%
99%
98%
86%
37° C.
35° C.
97%
78%
82%
87%
84%
37° C.
25° C.
130%
122%
121%
83%
69%
74%
60° C.
ambient
103%
109%
96%
85%
98%
97%
60° C.
35° C.
103%
102%
105%
96%
116%
60° C.
25° C.
121%
114%
125%
84%
81%
89%
Freeze-
25° C.
56%
40%
35%
33%
36%
dried
As can be seen from these results, experimental error gives rise to some variation in FIGURES, but these do nevertheless show very substantial retention of activity over prolonged storage and much better retention of activity than with freeze-dried material.
2.50 ml of ascorbate oxidase (21.25 mg protein) solution was prepared. To this was added 2.50 ml of Tris buffer pH 7.6 containing 21.25 mg Ficoll 400, giving a protein:Ficoll weight ratio of 1:1. This was then divided into ten 0.5 ml portions and dried at 37° C. under reduced pressure of about 80% of atmospheric for 24 hours. The samples were next heated, still under reduced pressure, for a further two hours at 60° C. Storage was on a laboratory shelf (temperature fluctuations between 17 and 28° C.). After varying periods of storage, samples were rehydrated by addition of 2.5 ml of 0.4 mM Na2HPO4 containing 0.5% Bovine serum albumin. It was then serially diluted to more of the same solution so that its activity would be 0.2 units/ml, if activity had been fully retained, and assayed. The activity relative to the starting value was determined.
Assay was carried out using a standard assay procedure published by Boeringer Mannheim. The assay monitors the decrease in absorbance at 245 nm as the enzyme catalyses the oxidation of a known solution of ascorbic acid. Enzyme which had been stored for 2 months at 35° C. was found, within the limits of experimental error, to have the same activity as enzyme which was stored for only a very short time.
Lactate dehydrogenase was incorporated into Ficoll 400 using the procedure of Example 5. The Ficoll:enzyme ratio was 0.23:0.26. Samples were stored for various periods and then recovered by adding 0.01M phosphate buffer in a quantity which would give a theoretical activity of 1 unit/ml, assuming full retention of activity. The recovered solutions were assayed using the procedure set out in Example 1. The measured activity of recovered material, as a percentage of the theoretical activity was:
Before
Storage period (days)
Drying
1
14
21
28
35
180
100%
91%
81%
91%
112%
97%
98%
Cytochrome C reductase was incorporated into Ficoll 400 by the procedure of Example 5. The ratio of enzyme:Ficoll was 1:1. Samples were subjected to an accelerated test, viz. stored for 14 days at 35° C., and then recovered by adding 4 ml of 0.2M KHCO3 to give a solution with a theoretical activity of 0.87 unit/ml assuming full retention of activity. The recovered material was assayed using a procedure given in “Methods in Enzymology” by Mahler, Volume II 1955 p. 688. It was found that the recovered material had an activity of 88% of the theoretical value.
Glycerol-3-phosphate dehydrogenase was incorporated into Ficoll 400 by the procedure of Examples. The ratio of enzyme:Ficoll was 1:2. Samples were subjected to an accelerated storage test by storage at 35° C. After 7 days storage the material was recovered by adding 0.05M Tris/HCl buffer at pH 7.6. This also contained 2 mg/ml albumin and 0.74 mg/ml EDTA. The recovered material was assayed using a procedure published by Biozyme Laboratories in which the enzyme catalyses the reaction:
##STR00001##
and the oxidation of NADH is followed spectrophotometrically at 340 nm.
It was found that after 7 days storage at 35° C. the activity was 96% of the activity of a control sample which was rehydrated immediately after being incorporated into Ficoll.
Alpha-glucosidase was incorporated into Ficoll 400 using the procedure of Example 5. The Ficoll:enzyme ratio was 1:1. As an accelerated test, samples were stored for various periods at 35° C. and then recovered by adding 4 mls of 0.067M phosphate buffer at pH 7.0 to give a solution whose theoretical activity, assuming full retention of activity, was 2 units/ml. The recovered solutions were assayed by a procedure described by H. Halvorson, Methods in Enzymology 8 559 (1966). The actual activity of recovered material relative to the theoretical value was:
Before
Storage period (days at 35° C.)
Drying
1
4
11
90
100%
100%
103%
95%
70%
Pyruvate: 5 g of Ficoll 400 was added to 20 ml of 10 mM sodium pyruvate solution. The solution was then divided into 40 portions, each containing 0.25 ml portions and processed in the manner described for Example 5 to give glasses.
NADH: 5 g of Ficoll 400 was added to 20 ml of a 2 mg/ml NADH solution. This was divided into 40 portions, each containing 0.25 ml, and processed as in Example 5 to give glasses.
At intervals following storage one sample of each reagent was rehydrated and the solutions mixed. They were assayed by the standard method described in Example 4. After 3 months storage at ambient temperature their ability to react in the LDH assay was 100% of the control value obtained at the initiation of storage.
NADH and pyruvate were processed as in Example 11. Portions of each resulting glass powder were mixed together. One such mixture was at once rehydrated and assayed by the procedure of Example 4. The reaction mixture consisted of 2.8 mls 0.01M phosphate buffer, 0.1 ml of rehydrated NADH/pyruvate mixture, and 0.1 mls of 1 unit/ml enzyme solution. The change in absorbance at 340 nm over three minutes was defined as 100%.
A further mixture was stored for one week and then rehydrated and assayed in the same way. Within the limits of experimental error, its activity was the same. Thus there had been no reaction of the NADH and pyruvate during storage.
A range of carrier materials were used in a standard procedure in which the stored active material is lactate dehydrogenase. In each case, a solution consisting of 0.05 g of carrier dissolved in 100 ml 0.01M phosphate buffer was prepared. 1 ml of 10 mg/ml lactate dehydrogenase solution was then added to 20 ml of the prepared solution. The solution thus created was divided into 0.5 ml aliquots in glass vials. These were dried under reduced pressure of about 80% atmospheric in a vacuum oven at 36° C. for 24 hours. After drying the vials were sealed and stored at ambient temperature. The product had a carrier:protein ratio by weight of 1:0.22.
Some samples were rehydrated immediately by addition of phosphate buffer. Others were stored for various lengths of time and then rehydrated. The activity of enzyme was determined as in Example 1. Activity of enzyme is expressed, in each case, as activity relative to that of enzyme rehydrated in the first week after drying. Results are set out in the following Table, in which “PVP” denotes polyvinylpyrollidone, “GPS” denotes 6-O-α-D-glucopyranosyl-D-sorbitol. “Palatinit” is a product of Südzucker Aktiengesellschaft, Mannheim-Ochsenfurt. Germany, and consisting of an equimolecular mixture of α-D-glucopyranosyl-1,6-mannitol and α-D-glucopyranosyl-1,6-sorbitol.
Storage period at 25° C. (weeks)
Carrier
1
2
3
4
5
6
8
10
12
16
Malto-
100
114
91
96
68
71
101
94
trose
Poly-
100
132
123
103
116
146
103
dextrose
Inulin
100
99
91
95
114
98
91
Stachy-
100
122
137
140
109
106
127
ose
Dextran
100
81
71
89
102
91
95
84
Sorbose
100
93
75
76
55
66
65
58
62
Poly-
100
100
80
71
53
62
55
63
acryl-
amide
PVP
100
75
76
70
62
GPS
100
124
Pala-
100
99
tinit
Franks, Felix, Hatley, Ross H. M.
Patent | Priority | Assignee | Title |
10064404, | Jun 10 2014 | BIOMATRICA, INC | Stabilization of thrombocytes at ambient temperatures |
10568317, | Dec 08 2015 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
10772319, | Jun 10 2014 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
11116205, | Dec 08 2015 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
11672247, | Jun 10 2014 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
12089588, | Dec 08 2015 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
12121022, | Jun 10 2014 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
7947649, | Apr 14 2008 | Advanced Technologies and Regenerative Medicine, LLC | Liquid buffered GDF-5 formulations |
7956028, | Dec 14 2006 | DePuy Orthopaedics, Inc; Depuy Spine, Inc; HAND INNOVATIONS LLC | Protein stabilization formulations |
7964561, | Jun 29 2007 | Advanced Technologies and Regenerative Medicine, LLC | Protein formulations for use at elevated temperatures |
8058237, | Aug 07 2007 | Advanced Technologies & Regenerative Medicine, LLC | Stable composition of GDF-5 and method of storage |
8435943, | Dec 14 2006 | Depuy Synthes Products, LLC | Protein stabilization formulations |
8895506, | Dec 14 2006 | Depuy Synthes Products, LLC | Protein stabilization formulations |
8900856, | Apr 08 2004 | BIOMATRICA, INC | Integration of sample storage and sample management for life science |
9078426, | Apr 08 2004 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
9376709, | Jul 26 2010 | BIOMATRICA, INC | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
9725703, | Dec 20 2012 | MXCGLOBAL INC | Formulations and methods for stabilizing PCR reagents |
9845489, | Jul 26 2010 | BIOMATRICA, INC | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
9999217, | Jul 26 2010 | BIOMATRICA, INC | Compositions for stabilizing DNA, RNA, and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
Patent | Priority | Assignee | Title |
125714, | |||
1855591, | |||
2457036, | |||
2648609, | |||
3300474, | |||
3413198, | |||
3456050, | |||
3480468, | |||
3554767, | |||
3694547, | |||
4157386, | May 18 1978 | Soft, chewable lozenge forming a sticky coating on teeth when combined with saliva in the mouth which is removable only by brushing | |
4372942, | Aug 13 1981 | BEECHAM INC A CORP OF | Candy base and liquid center hard candy made therefrom |
4423086, | Oct 17 1979 | Roquette Freres | Process for hard coating with sorbitol and products obtained thereby |
4551329, | Jan 20 1984 | Joan, Harris | Oral medicament lollipop |
4587267, | Sep 15 1983 | Standard Telephones and Cables Public Limited Company | Controlled release system |
4741872, | May 16 1986 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | Preparation of biodegradable microspheres useful as carriers for macromolecules |
4749575, | Oct 03 1983 | Bio-Dar Ltd. | Microencapsulated medicament in sweet matrix |
4753790, | Dec 16 1986 | Cadbury Adams USA LLC | Sorbitol coated comestible and method of preparation |
4762719, | Aug 07 1986 | Powder filled cough product | |
4824938, | Jun 06 1984 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Water-soluble dry solid containing proteinaceous bioactive substance |
4847090, | Nov 07 1986 | Warner-Lambert Company | Confection product and method for making same |
4849225, | Jul 10 1986 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Process to prepare solid products containing oil-soluble substance |
4863865, | Aug 26 1983 | PAFRA LIMITED, | Preservation by cold storage |
4873085, | Apr 20 1987 | Fuisz Technologies Ltd | Spun fibrous cosmetic and method of use |
4891319, | Jul 09 1985 | Quadrant Drug Delivery Limited | Protection of proteins and the like |
4898781, | Nov 07 1986 | NOVOZYMES A S | Water-soluble microcapsules |
4910135, | Nov 21 1985 | Boehringer Mannheim GmbH | Water-soluble peroxidase derivatives |
4963359, | Jan 30 1989 | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC | Non-cariogenic confections |
4985252, | Apr 07 1987 | R I PH RECHERCHE INFORMATIQUE ET PHARMACIE S A R L | Medication, dietetic product and hygienic product in the form of a powered composition obtained by adsorption of active ingredients on a rapidly dissolving sugar and process for obtaining said composition |
4997654, | Aug 14 1989 | ADAMS CONFECTIONERY CORP ; ADAMS USA INC | Method for increasing salivation for xerostomia patients |
586504, | |||
DE159826, | |||
EP111216, | |||
EP140489, | |||
EP229810, | |||
EP297887, | |||
EP520748, | |||
EP223221, | |||
EP244771, | |||
EP252750, | |||
GB2126588, | |||
JP7012153, | |||
JPHO5597096, | |||
RE37872, | Feb 16 1989 | Novartis Pharma AG | Storage of materials |
WO8600336, | |||
WO8604095, | |||
WO8700196, | |||
WO8705300, | |||
WO8906542, | |||
WO9005182, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Aug 28 2001 | Nektar Therapeutics | (assignment on the face of the patent) | / | |||
Jan 13 2003 | INHALE THERAPEUTIC SYSTEMS, INC | Nektar Therapeutics | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 013525 | /0753 | |
Dec 31 2008 | Nektar Therapeutics | Novartis Pharma AG | ASSIGNMENT OF PATENT RIGHTS | 022071 | /0001 |
Date | Maintenance Fee Events |
Date | Maintenance Schedule |
Feb 27 2010 | 4 years fee payment window open |
Aug 27 2010 | 6 months grace period start (w surcharge) |
Feb 27 2011 | patent expiry (for year 4) |
Feb 27 2013 | 2 years to revive unintentionally abandoned end. (for year 4) |
Feb 27 2014 | 8 years fee payment window open |
Aug 27 2014 | 6 months grace period start (w surcharge) |
Feb 27 2015 | patent expiry (for year 8) |
Feb 27 2017 | 2 years to revive unintentionally abandoned end. (for year 8) |
Feb 27 2018 | 12 years fee payment window open |
Aug 27 2018 | 6 months grace period start (w surcharge) |
Feb 27 2019 | patent expiry (for year 12) |
Feb 27 2021 | 2 years to revive unintentionally abandoned end. (for year 12) |